Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above
Sponsor: CHA Vaccine Institute Co., Ltd.
Summary
To evaluate the immunogenicity of the investigational product (IP) in healthy adults aged 50 years or older and to explore differences in immune responses between the experimental and control groups, and to determine the optimal dose of the IP.
Official title: A Multicenter, Active-controlled, Randomized, Double Blinded, Parallel, Phase II Study to Assess the Immunogenicity and Safety of CVI-VZV-001 in Healthy Adults Aged 50 Years and Above
Key Details
Gender
All
Age Range
50 Years - Any
Study Type
INTERVENTIONAL
Enrollment
135
Start Date
2026-04
Completion Date
2027-01
Last Updated
2026-03-19
Healthy Volunteers
Yes
Conditions
Interventions
Shingrix
Licensed herpes zoster vaccine used as an active comparator.
CVI-VZV-001
Investigational herpes zoster vaccine.
Locations (7)
Kyungpook National University Chilgok Hospital
Daegu, Daegu, South Korea
CHA Bundang Medical Center
Seongnam-si, Gyeonggi-do, South Korea
Yongin Severance Hospital, Yonsei University Health System
Yongin, Gyeonggi-do, South Korea
Jeonbuk National University Hospital
Jeonju, Jeollabuk-do, South Korea
The Catholic University of Korea Eunpyeong St. Mary's Hospital
Seoul, Seoul, South Korea
Chung-Ang University Hospital
Seoul, Seoul, South Korea
Ewha Womans University Seoul Hospital
Seoul, Seoul, South Korea